CEO Linda Marban dismissed concerns that Deramiocel would receive a conditional approval, citing a trial that met both primary and key secondary endpoints. ・The company is preparing for a potential ...

When it comes to short-term investing or trading, they say "the trend is your friend." And there's no denying that this is the most profitable strategy. But making sure of the sustainability of a ...

Capricor Therapeutics (CAPR) closed the last trading session at $13.47, gaining 7.6% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by ...

While "the trend is your friend" when it comes to short-term investing or trading, timing entries into the trend is a key determinant of success. And increasing the odds of success by making sure the ...

Capricor Therapeutics (CAPR) shares soared 5.3% in the last trading session to close at $6.52. The move was backed by solid volume with far more shares changing hands than in a normal session. This ...

Capricor Therapeutics shares are trading lower by 6.05% during Thursday's session. The company earlier commenced its public offering of common stock. Market-moving news hits Benzinga Pro first—get a ...

Whales with a lot of money to spend have taken a noticeably bullish stance on Capricor Therapeutics. Looking at options history for Capricor Therapeutics (NASDAQ:CAPR) we detected 13 trades. If we ...

Shares of Capricor Therapeutics CAPR have skyrocketed 281.9% this week. The massive stock price surge was observed after the company reported positive top-line results from a late-stage study of ...

What is the current share price of Capricor Therapeutics (CAPR)? Capricor Therapeutics's (CAPR) current share price is $11.25. This constitutes a price movement of 19.55% when compared to the share ...

We recently published a list of 10 Best Multibagger Stocks To Buy Heading into 2025. In this article, we are going to take a look at where Capricor Therapeutics, Inc. (NASDAQ:CAPR) stands against ...